SMMT Jan 2025 1.000 call
| Previous Close | 5.30 |
| Open | 5.30 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 1.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 5.30 - 5.30 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 691 |
ZacksSummit (SMMT) Stock Surges 57% in the Past Month: Here's Why
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
Business WireSummit Raises $200 Million; Also Expands License Territories for Ivonescimab
MIAMI, June 03, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the Company received and accepted an unsolicited offer from an institutional investor to purchase 22,222,222 shares of the Company’s common stock at $9.00 per share, a premium to the closing price on Friday, May, 31, 2024, for aggregate gross proceeds to the Company of approximately $200.0 million.
Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
MIAMI, June 01, 2024--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") announced that the Journal of the American Medical Association (JAMA) published a manuscript titled, "Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer with EGFR Variant: A Randomized Clinical Trial." The publication is based on the results of HARMONi-A, a single region, multi-center, Phase III study conducted in China sponsored by Akeso, Inc. (Akeso, HKEX Code: 9926.HK), with data generate
